Ueno K, Shinoda I, Takahashi Y, Kawamoto S, Yamamoto N, Kuriyama M, Kawada Y, Nagatani Y, Takeuchi T, Sakai S
Dept. of Urology, Gifu University School of Medicine.
Gan To Kagaku Ryoho. 1990 Aug;17(8 Pt 2):1783-7.
Ten patients with relapsed and hormone-resistant prostate cancer were given intra-arterial infusion with, mainly, cisplatin using the reservoir system. The tip of the indwelling infusion catheter was inserted from the femoral artery into the internal iliac artery or common iliac artery. The opposite end of the infusion catheter was connected to a reservoir implanted subcutaneously at the thigh portion. Combination chemotherapy using methotrexate, adriamycin and cisplatin (MAC therapy) was mainly performed. According to criteria of the Jpn. Assoc. for Cancer Ther., the response rate was 23%, including 3 or PR cases. Regarding the survival rate, the 1-year survival rate was 66.7% and the 2-year rate was 33.3%. Concerning adverse reactions, nausea, vomiting and anorexia were noted in all cases. Stomatitis, leukopenia and thrombocytopenia were also found in 38%. We consider that the IA-MAC therapy is one of the most useful regimen for the treatment of the relapsed and/or hormone-resistant prostate cancer.
10例复发且激素抵抗型前列腺癌患者使用储液器系统进行了主要以顺铂为主的动脉内灌注治疗。留置灌注导管的尖端从股动脉插入髂内动脉或髂总动脉。灌注导管的另一端与植入大腿部皮下的储液器相连。主要采用了甲氨蝶呤、阿霉素和顺铂联合化疗（MAC疗法）。根据日本癌症治疗协会的标准，缓解率为23%，包括3例部分缓解（PR）病例。关于生存率，1年生存率为66.7%，2年生存率为33.3%。关于不良反应，所有病例均出现恶心、呕吐和厌食。38%的病例还出现了口腔炎、白细胞减少和血小板减少。我们认为IA-MAC疗法是治疗复发和/或激素抵抗型前列腺癌最有效的方案之一。
